Navigation Links
Tiny shock absorbers help bacteria stick around inside the body

Bacteria have hair-like protrusions with a sticky protein on the tip that lets them cling to surfaces. The coiled, bungee cord-like structure of the protrusions helps the bacteria hang on tightly, even under rough fluid flow inside the body, researchers report in the journal PLoS Biology.

A group of researchers at the University of Washington in Seattle and ETH Zurich in Switzerland have been studying how the bacterium E. coli attaches to mucous membranes in the body. In their previous research, they explained how the protrusions, known as fimbriae, have an adhesive protein called FimH at their tip that binds in an unusual way to a sugar molecule on a surface.

The FimH-sugar combination makes a "catch bond" that acts like a finger trap, and actually gets stronger as drag force is exerted on a bacterium. Rather than being swept away by fluids moving through the human body, the bacterium grips even more tightly, helping it stick around and form an infection, like those seen in the urinary tract, for instance. The catch bonds release their grip when there is little or no force on the bacteria.

In new research, the scientists have learned that the mechanical properties of the bungee-like fimbriae also play a key role in the tenacity of E. coli clinging to mucousal surfaces. The tiny fiber-like protrusions are made up of interlocking protein segments in a tightly coiled helix shape, like a seven-nanometer-wide Slinky toy. The researchers found that under force, the fimbriae stretch to many times their original length as the protein segments uncoil one by one. If the force on them drops, the fimbriae coils are compressed, keeping tension on the bond between the bacterium and the mucous membrane.

"The fimbriae uncoil and recoil to dampen sudden changes in forces caused by rough and rapidly changing flow conditions," explained study co-author Dr. Viola Vogel, professor in the Department of Materials at ETH Zurich. This process maintains an
'"/>

Source:University of Washington


Page: 1 2

Related biology news :

1. Researches discover gene critical for protection against septic-shock-induced death
2. Heat-shock protein vaccine reduces alveolar bone loss
3. Its in your head: The brains own globin defends you from shock and stroke
4. Anti-bacterial additive widespread in U.S. waterways
5. A bacterial genome reveals new targets to combat infectious disease
6. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
7. Scientists discover that host cell lipids facilitate bacterial movement
8. Family trees of ancient bacteria reveal evolutionary moves
9. Drug-resistant bacteria on poultry products differ by brand
10. Programmable cells: Engineer turns bacteria into living computers
11. NASA links nanobacteria to kidney stones and other diseases

Post Your Comments:
(Date:11/23/2009)...ciated strain of the deadly superbug MRSAan infect...bioticsposes a far greater health threat than prev... according to a study in the December issue of Em...s easily picked up in fitness centers, schools, an...l burden of MRSA within hospitals, the report foun...
(Date:11/23/2009)...gests that a common oral bacterium may exacerbate ... et al, "Unique Lipids from a Common Human Bacteri...f Enhancing Autoimmunity," appears in the December.... , Multiple sclerosis (MS), a disease where the...affects nearly 1 in 700 people in the United State...
(Date:11/23/2009)... University of Alabama at Birmingham (UAB) researc...ing medical conditions (co-morbidity) do not expla...mericans compared to Caucasians who also have colo... Cancer , a journal of the American Cancer Societ... co-morbidity are independent predictors of poor s...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 1VIASPACE Pursuing Renewable Energy Business in Asia 13353 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 1Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 2Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 4Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 5Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 6Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 1Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 2Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 3Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 4Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 5Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 6Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 7Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 8Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 9Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 10Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 11Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 12Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 13Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 14Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 15Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 16Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 17Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 18Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 19Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 20Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 21Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 22Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 23
...veling the complex mechanisms in the brain that re...etites are controlled by systems very similar to t...type of neuron that is essential for feeding behav... and undergo rapid weight loss. , Remarkably, th...only influenced eating behavior when they were rem...
...des insight into genetic basis of human diseaseHig...lds a map of genetic variation which can give clue...he current technologies collect genotypes, or info...t many scientists believe that drilling down to th... of each chromosome -- so-called haplotypes -- wil...
...he last ice age are the likely culprits in the ext...rican great mammals such as mammoths, mastodons an...da researcher. , Determining whether the first arr...inent at the end of the last Ice Age was responsib...d scientists because both events occurred at the s...
Other Biology News:An essential regulator of body weight revealed 2An essential regulator of body weight revealed 3An essential regulator of body weight revealed 4California computer scientists double volume of data in NIH biotech repository 2California computer scientists double volume of data in NIH biotech repository 3California computer scientists double volume of data in NIH biotech repository 4Study shows big game hunters, not climate change, killed off sloths 2Study shows big game hunters, not climate change, killed off sloths 3
(Date:11/24/2009)...dBLENHEIM,Ontario,Nov.24/PRNewswire-FirstCall/--Do...ssetsofHylandSeeds,adivisionofThompsonsLimitedofBl...expandDowAgroSciences,currentseedsbusinessasthecom... 2010 andDowAgroSciencesHerbicideTolerantTraitTec...dinthenearfuture. ,, "Thisacquisitionbringstoge...
(Date:11/24/2009)...Nov.24/PRNewswire-Asia/--NODPharmaceuticalsInc.ann...wedthepatentapplicationfor,itsnano-particleoraldel...yefficientapproachtoincorporatepeptidesor,proteins...ofdrugs,otherwiseadministeredasinjections.NODtechn...acromoleculardrugssuchasinsulin,interferon,growth...
(Date:11/24/2009)...ficacyendpointhasbeenmetforpatientswithadvanced-st...Y,Nov.24/PRNewswire-FirstCall/-AEternaZentarisInc....armaceuticalcompanyfocusedonendocrinetherapyandonc...2studywithitstargetedcytotoxicpeptideconjugate,AEZ...rrentendometrialcancer.Inapersonalizedhealthcareap...
(Date:11/24/2009)...ly,November24/PRNewswire/--HealthRoboticstodayanno...groupofselected,investors.ThisrecentlyformedToront...csCanada,Inc.andwillmarket,install,andsupport,Heal...sthe,revolutionaryproductofferingsi.v.STATION(TM),...illalsoprovideassistanceonan"asneeded,basis"toitss...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...ONDON, Aug. 27 Following the successful acquisiti...ry, Chiltern, a leading,contract research organiza... its two early Phase units into a single operation... Phase is providing high quality early phase servi...ll established units in Slough,(just outside of Lo...
...AN DIEGO and INDIANAPOLIS, Aug. 26 Amylin,Pharmac...Company (NYSE: LLY ),in a conference call today p...ng the August 18, 2008 U.S. Food and Drug Administ... (exenatide) injection referencing,pancreatitis. T...referenced,in the alert, as well as others, and pr...
...otes Secured by Royalties on U.S. Sales of SANCTUR...26 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV )...ement to institutional investors of $105.0 million...e secured by royalties to be,paid from sales in th...,(trospium chloride). SANCTURA and SANCTURA XR are...
Other Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 2Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 3Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 4
Rabbit Anti-Schizosaccharomyces pombe SpUlp2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Human STX18 Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-Human sRANKL Polyclonal Antibody, Biotin Conjugated from Cell Sciences
Mouse Anti-CD42d Monoclonal Antibody, Unconjugated, Clone CLB-SW16 (formerly 708) from Abcam
Biology Products: